$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224001431 Filed on March 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$3.000K	$9.000K
YoY Change		-83.87%	-89.84%
Cost Of Revenue	$0.00	$1.200K	$3.600K
YoY Change		-78.95%	-87.36%
Gross Profit	$0.00	$1.800K	$5.400K
YoY Change		-86.05%	-91.02%
Gross Profit Margin		60.0%	60.0%
Selling, General & Admin	$671.5K	$1.399M	$3.560M
YoY Change	-12.91%	55.48%	-9.72%
% of Gross Profit		77706.11%	65931.65%
Research & Development	$422.4K	$349.4K	$1.971M
YoY Change	32.4%	-93.01%	-68.56%
% of Gross Profit		19411.67%	36493.31%
Depreciation & Amortization	$29.27K	$24.58K	$94.58K
YoY Change	27.15%	6.78%	2.72%
% of Gross Profit		1365.56%	1751.48%
Operating Expenses	$1.123M	$1.774M	$5.626M
YoY Change	0.91%	-64.53%	-45.41%
Operating Profit	-$1.123M	-$1.772M	-$5.620M
YoY Change	0.91%	-64.47%	-45.14%
Interest Expense	$0.00	$93.27K	$333.6K
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	$81.60K		$333.6K
YoY Change	33.45%		232.47%
Pretax Income	-$1.042M	-$1.679M	-$5.287M
YoY Change	-0.99%	-72.99%	-47.88%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.042M	-$1.679M	-$5.287M
YoY Change	-0.99%	-72.99%	-47.88%
Net Earnings / Revenue		-55952.33%	-58739.71%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.73	-$1.22	-$3.76
COMMON SHARES
Basic Shares Outstanding	1.357M shares	1.382M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.007M	$9.987M	$9.987M
YoY Change	-5.35%	20.03%	20.03%
Cash & Equivalents	$9.007M	$3.467M
Short-Term Investments	$0.00	$6.520M	$6.520M
Other Short-Term Assets	$190.6K	$277.3K	$277.3K
YoY Change	-96.4%	-97.34%	-97.34%
Inventory	$6.594K	$6.594K	$6.590K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$9.205M	$10.27M	$10.27M
YoY Change	-37.86%	-45.21%	-45.21%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$3.280K	$3.280K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$415.0K	$444.3K	$444.3K
YoY Change	-0.2%	1.23%	1.23%
TOTAL ASSETS
Total Short-Term Assets	$9.205M	$10.27M	$10.27M
Total Long-Term Assets	$415.0K	$444.3K	$444.3K
Total Assets	$9.620M	$10.72M	$10.72M
YoY Change	-36.84%	-44.15%	-44.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$336.8K	$317.3K	$317.3K
YoY Change	-4.69%	-90.29%	-90.29%
Accrued Expenses	$39.92K	$39.92K	$39.92K
YoY Change	0.0%	0.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$391.0K	$371.4K	$371.4K
YoY Change	-4.07%	-88.82%	-88.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$391.0K	$371.4K	$371.4K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$391.0K	$371.4K	$371.4K
YoY Change	-4.07%	-88.82%	-88.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.14M	-$59.10M
YoY Change	9.62%	9.82%
Common Stock	$1.431K	$1.431K
YoY Change	-89.83%	-89.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$271.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.229M	$10.34M	$10.34M
YoY Change
Total Liabilities & Shareholders Equity	$9.620M	$10.72M	$10.72M
YoY Change	-36.84%	-44.15%	-44.15%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.042M	-$1.679M	-$5.287M
YoY Change	-0.99%	-72.99%	-47.88%
Depreciation, Depletion And Amortization	$29.27K	$24.58K	$94.58K
YoY Change	27.15%	6.78%	2.72%
Cash From Operating Activities	-$896.9K	-$1.898M	-$8.028M
YoY Change	-76.65%	-47.15%	2.96%
INVESTING ACTIVITIES
Capital Expenditures		$100.0K	$100.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$6.520M	$1.225M	$3.545M
YoY Change	29.44%	-124.23%	-135.18%
Cash From Investing Activities	$6.520M	$1.125M	$3.445M
YoY Change	29.44%	-122.25%	-134.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$271.0K
YoY Change			-98.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$82.80K	-271.0K	-$271.0K
YoY Change			-101.75%
NET CHANGE
Cash From Operating Activities	-$896.9K	-1.898M	-$8.028M
Cash From Investing Activities	$6.520M	1.125M	$3.445M
Cash From Financing Activities	-$82.80K	-271.0K	-$271.0K
Net Change In Cash	$5.541M	-1.044M	-$4.854M
YoY Change	363.38%	-87.93%	101.95%
FREE CASH FLOW
Cash From Operating Activities	-$896.9K	-$1.898M	-$8.028M
Capital Expenditures		$100.0K	$100.0K
Free Cash Flow		-$1.998M	-$8.128M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5286574	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10144044	usd
CY2023	us-gaap	Gross Profit GrossProfit	5400	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3560309	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	5625532	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	68746	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2023Q4	us-gaap	Cash Cash	3466867	usd
CY2022Q4	us-gaap	Cash Cash	8320519	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15864674	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	40000	usd
CY2022	celz	Amortization Expenses AmortizationExpenses	48440	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-53500
CY2023	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0622284
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	211 E Osborn Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Phoenix
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85012
CY2023	dei	City Area Code CityAreaCode	480
CY2023	dei	Local Phone Number LocalPhoneNumber	399-2822
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	CELZ
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6633274	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1356626	shares
CY2023	dei	Auditor Name AuditorName	Haynie & Company
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023	dei	Auditor Firm AuditorFirmId	457
CY2023Q4	us-gaap	Investments Investments	6520191	usd
CY2022Q4	us-gaap	Investments Investments	10078617	usd
CY2023Q4	celz	Due To Related Party Current DueToRelatedPartyCurrent	14194	usd
CY2022Q4	celz	Due To Related Party Current DueToRelatedPartyCurrent	14194	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371394	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3321652	usd
CY2023Q4	us-gaap	Liabilities Liabilities	371394	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3321652	usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1431126	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1407625	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1373626	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1407624	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1431	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1407	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69711749	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59098432	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	270952	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10715190	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19186326	usd
CY2023	us-gaap	Revenues Revenues	9000	usd
CY2022	us-gaap	Revenues Revenues	88600	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	3600	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	28491	usd
CY2022	us-gaap	Gross Profit GrossProfit	60109	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1970639	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6268854	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3943543	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94584	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10304481	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5620132	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10244372	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	333558	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	100328	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	333558	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	100328	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5286574	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10144044	usd
CY2023	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2023	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-3.76
CY2022	celz	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-9.28
CY2023	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1407632	shares
CY2022	celz	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	1093204	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	usd
CY2022	celz	Issuance Of Common Stock And Accompanying Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount	15471775	usd
CY2022	celz	Common Stock Issued For Related Party Management And Patent Liabilities Amount CommonStockIssuedForRelatedPartyManagementAndPatentLiabilitiesAmount	250000	usd
CY2022	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	457	usd
CY2022	celz	Stock Based Compensation StockBasedCompensation	68746	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10144044	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15864674	usd
CY2023	celz	Round Up Shares Issued In Reverse Stock Split Amount RoundUpSharesIssuedInReverseStockSplitAmount	0	usd
CY2023	celz	Purchase Of Common Stock PurchaseOfCommonStock	-270952	usd
CY2023	celz	Stock Based Compensation StockBasedCompensation	36648	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5286574	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10343796	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5286574	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10144044	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	36648	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94584	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	34087	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2485	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3600	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-672	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-108202	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	338120	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2950258	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2505676	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15535	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8027885	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7796966	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	22854815	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10078617	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	26400000	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	100000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3445185	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10078617	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15471775	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	457	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	270952	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-270952	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15472232	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4853652	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2403351	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8320519	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10723870	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3466867	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8320519	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	0	usd
CY2022	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	250000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates – </strong></em>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	34000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	we effected a 1-for-10 reverse split of our authorized and issued and outstanding shares of common stock
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	40000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1970639	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6268854	usd
CY2016Q1	celz	Number Of Share Exchange NumberOfShareExchange	43112	shares
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	100000	usd
CY2017Q2	celz	Payments Upon Completion Of Irb Clinical Trial PaymentsUponCompletionOfIrbClinicalTrial	200000	usd
CY2020Q4	celz	Company Paid CompanyPaid	50000	usd
CY2023Q4	celz	Company Paid CompanyPaid	50000	usd
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2021Q3	celz	Company Paid CompanyPaid	40000	usd
CY2021Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2023Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2021Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	300000	usd
CY2023	celz	Payments In The Event Of Commercialization Of Technology PaymentsInTheEventOfCommercializationOfTechnology	400000	usd
CY2023	celz	Amortization Expenses AmortizationExpenses	48440	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	207936	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56000	usd
CY2020Q4	us-gaap	Payments For Fees PaymentsForFees	250000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	102085	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	101774	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	64650	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	40000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	35000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	97502	usd
CY2023Q4	celz	Future Amortization Cost FutureAmortizationCost	441011	usd
CY2022Q4	celz	Licensing Agreements LicensingAgreements	760000	usd
CY2022Q4	celz	Accumulated Amortization Of Licensing Agreements AccumulatedAmortizationOfLicensingAgreements	-324405	usd
CY2023	celz	Addition Of New Assets AdditionOfNewAssets	100000	usd
CY2023	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2023	celz	Accumulated Amortization AccumulatedAmortization	-94584	usd
CY2023Q4	celz	Licensing Agreements LicensingAgreements	860000	usd
CY2023Q4	celz	Accumulated Amortization Of Licensing Agreements AccumulatedAmortizationOfLicensingAgreements	-418989	usd
CY2022Q4	celz	Cost Of Purchased Equipment CostOfPurchasedEquipment	5000000	usd
CY2022Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5000000	usd
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	299167	shares
CY2022Q2	celz	Purchase Of Warrants Shares PurchaseOfWarrantsShares	456389	shares
CY2022Q2	celz	Purchase Of Pre Funded Warrant And Related Common Warrant PurchaseOfPreFundedWarrantAndRelatedCommonWarrant	1511112	shares
CY2022Q2	celz	Description Of Amendment DescriptionOfAmendment	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
CY2023	celz	Common Warrants Exercise Price CommonWarrantsExercisePrice	20.00
CY2023	celz	Pre Funded Warrants Exercise Price PreFundedWarrantsExercisePrice	0.0001
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0081	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.9295	pure
CY2023Q4	us-gaap	Share Price SharePrice	18.30
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	5000000	usd
CY2022Q4	celz	Initial Payment Amount InitialPaymentAmount	2000000	usd
CY2022Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	5000000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	1082622	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	2096475	usd
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	300783	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	582461	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1383405	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2678936	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6266742	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4843337	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6266742	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4843337	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.262	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.264	pure
CY2023	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd

Files In Submission

Name	View Source	Status
R22.htm	Edgar Link	pending
0001477932-24-001431-index-headers.html	Edgar Link	pending
0001477932-24-001431-index.html	Edgar Link	pending
0001477932-24-001431.txt	Edgar Link	pending
0001477932-24-001431-xbrl.zip	Edgar Link	pending
celz-20231231.xsd	Edgar Link	pending
celz_10k.htm	Edgar Link	pending
celz_10kimg1.jpg	Edgar Link	pending
celz_10kimg2.jpg	Edgar Link	pending
celz_10kimg3.jpg	Edgar Link	pending
celz_ex108.htm	Edgar Link	pending
celz_ex109img1.jpg	Edgar Link	pending
celz_ex109img10.jpg	Edgar Link	pending
celz_ex109img11.jpg	Edgar Link	pending
celz_ex109img12.jpg	Edgar Link	pending
celz_ex109img2.jpg	Edgar Link	pending
celz_ex109img3.jpg	Edgar Link	pending
celz_ex109img4.jpg	Edgar Link	pending
celz_ex109img5.jpg	Edgar Link	pending
celz_ex109img6.jpg	Edgar Link	pending
celz_ex109img7.jpg	Edgar Link	pending
celz_ex109img8.jpg	Edgar Link	pending
celz_ex109img9.jpg	Edgar Link	pending
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
celz_ex44.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
celz-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celz_10k_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
celz-20231231_pre.xml	Edgar Link	unprocessable
celz-20231231_cal.xml	Edgar Link	unprocessable
celz-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2024 Q1 Form 10-K Financial Statement

#000147793224001431 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2024 Q1 Form 10-K Financial Statement

#000147793224001431 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz